Biorestorative Therapies (NASDAQ:BRTX) Posts Earnings Results, Meets Estimates

Biorestorative Therapies (NASDAQ:BRTX) issued its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.37), Zacks reports. Biorestorative Therapies had a negative return on equity of 231.08% and a negative net margin of 3,308.09%.The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.15 million.

Biorestorative Therapies Price Performance

BRTX stock traded down $0.01 during midday trading on Friday, hitting $0.29. 875,205 shares of the stock traded hands, compared to its average volume of 9,431,650. Biorestorative Therapies has a 1-year low of $0.19 and a 1-year high of $2.05. The stock’s fifty day simple moving average is $0.56 and its 200-day simple moving average is $1.07. The firm has a market cap of $2.61 million, a P/E ratio of -0.20 and a beta of 0.47.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Virtu Financial LLC lifted its position in shares of Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares in the last quarter. DRW Securities LLC purchased a new stake in Biorestorative Therapies in the 4th quarter worth $55,000. Finally, Citadel Advisors LLC acquired a new position in Biorestorative Therapies during the third quarter worth $152,000. 69.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.